LTZ Therapeutics Secures $20M+ Series A for Myeloid Engager Immunotherapy Development

LTZ Therapeutics, a company specializing in immunotherapy, has announced the completion of its Series A financing, securing over $20 million to further their innovative Myeloid Engager pipeline aimed at treating cancer and autoimmune diseases. This significant funding round was led by new investor Lapam Capital, with additional investments from GL Ventures, K2 Venture Partners, and Shunwei Capital. This latest round of investment brings LTZ’s total funding to approximately $50 million since its inception in 2022.

The newly acquired funds will be utilized to expedite the development of LTZ's pipeline. Key initiatives include supporting the company's Investigational New Drug (IND) process, initiating Phase 1 clinical trials for LTZ’s leading asset, LTZ-301, and advancing IND-enabling work for another promising asset, LTZ-232. Additionally, the financing will support the progression of other early-stage discovery programs and expand the company's team.

Robert Li, Ph.D., Founder and CEO of LTZ, emphasized the significance of this funding round in advancing their novel Myeloid Engager Platform. "This round represents an important step forward in the development of our novel Myeloid Engager Platform for cancer and other conditions with unmet medical needs," Li stated. He highlighted that their approach combines reverse translational science with a robust understanding of tumor microenvironment (TME) biology, particularly focusing on myeloid biology. Over the past year, LTZ has made substantial progress, validating its platform through various preclinical tests, including cancer patient-derived organoid models. They have also advanced their lead asset, LTZ-301, from the discovery stage to an IND-enabling stage. Li expressed gratitude for the ongoing support from their scientific team, advisory board, and investors, which has been instrumental in their achievements.

Macrophages are a crucial component of the immune cell populations within the TME of various hematologic and solid tumors. Engaging and activating these macrophages to destroy cancer cells holds significant therapeutic potential. Based on reverse translational research and the evolving understanding of myeloid biology in the TME across a broad spectrum of cancer types, LTZ is developing its Myeloid Engager Platform. This platform primarily aims to enhance the phagocytic function of monocytes and macrophages, thereby fostering anti-tumor immunity.

Zhihua Yu, Founding Partner at Lapam Capital, commended the expertise and dedication of the LTZ team. "LTZ comprises a highly skilled and passionate team that brings together a unique complement of expertise," Yu noted. He expressed excitement about LTZ's reverse translational approach, which aims to maximize the therapeutic potential of their assets. Yu highlighted that the Myeloid Engager Platform and LTZ's pipeline have the potential to significantly impact the future of immunotherapy development. The platform aims to rebalance the immune system and improve patient outcomes. Preclinical results have shown promising clinical benefits, indicating that LTZ's model could be applicable to a wide range of cancer types (both liquid and solid) and autoimmune diseases, addressing areas with substantial unmet medical needs.

LTZ Therapeutics is an immunotherapy-focused biotech company committed to developing novel therapies using their innovative Myeloid Engager Platform. The company aims to improve clinical outcomes for patients with cancer and autoimmune diseases. With main operations in Redwood City, California, and Shenzhen, China, as well as a team in Heidelberg, Germany, LTZ is dedicated to creating immunotherapies capable of overcoming resistance and enhancing anti-tumor immunity through a combination of reverse translational science and emerging disease biology of the tumor microenvironment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!